neoantigen DNA vaccine
/ Imunon
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
A novel formulated neoantigen DNA vaccine with promising anticancer efficacy in B16F10 mouse melanoma model
(AACR 2025)
- "All animals in the adjuvant groups also lived longer. The anti-tumor efficacy results are supported by the onset of robust T-cell responses in all treatment groups supporting the involvement of immune activation in the action of this novel DNA vaccine that does not require a virus or device and can be manufactured rapidly with a simple and cost-effective manufacturing process critical for the viability of cancer vaccines."
Preclinical • Tumor-specific neoantigens • Melanoma • Oncology • Solid Tumor • IL12A
1 to 1
Of
1
Go to page
1